相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HMGA2 as a Critical Regulator in Cancer Development
Behzad Mansoori et al.
GENES (2021)
miR-330 suppresses EMT and induces apoptosis by downregulating HMGA2 in human colorectal cancer
Behzad Mansoori et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Monica Alvarez-Fernandez et al.
CANCER CELL (2020)
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Lei Ding et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
Zheng Fan et al.
SCIENCE ADVANCES (2020)
HMGA2-mediated tumorigenesis through angiogenesis in leiomyoma
Yinuo Li et al.
FERTILITY AND STERILITY (2020)
CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer
Yi Li et al.
CANCER LETTERS (2020)
Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling
Haijun Wu et al.
CANCER MEDICINE (2019)
Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression
Jianchu Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13
Monika Novakova et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
Kai Zhang et al.
CANCER LETTERS (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells
Ahrum Min et al.
CANCER LETTERS (2018)
CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients
Xiuqing Dong et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects
Tomoko Uehara et al.
EUROPEAN JOURNAL OF MEDICAL GENETICS (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer
Wenyan Zhao et al.
CANCER MEDICINE (2018)
Prognostic Value of HMGA2 in Human Cancers: A Meta-Analysis Based on Literatures and TCGA Datasets
Ben Huang et al.
FRONTIERS IN PHYSIOLOGY (2018)
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
Mei Zeng et al.
ELIFE (2018)
HMGA2 regulates epithelial-mesenchymal transition and the acquisition of tumor stem cell properties through TWIST1 in gastric cancer
Wei Li et al.
ONCOLOGY REPORTS (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinicopathological and prognostic significance of HMGA2 overexpression in gastric cancer: a meta-analysis
Jingyi Zhu et al.
ONCOTARGET (2017)
Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders
Bret L. Bostwick et al.
GENOME MEDICINE (2017)
HMGA2 promotes vasculogenic mimicry and tumor aggressiveness by upregulating Twist1 in gastric carcinoma
Junying Sun et al.
SCIENTIFIC REPORTS (2017)
HMGA2-FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer
Jiaqiang Dong et al.
CLINICAL CANCER RESEARCH (2017)
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto et al.
NATURE REVIEWS CANCER (2017)
Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML
Li Tan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Tinghu Zhang et al.
NATURE CHEMICAL BIOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The HMGA proteins: A myriad of functions (Review)
Isabelle Cleynen et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells
Sabine Hombach-Klonisch et al.
FRONTIERS IN ENDOCRINOLOGY (2014)
Effect of silencing of high mobility group A2 gene on gastric cancer MKN-45 cells
Chun-Hui Wei et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Hmga2 Promotes Neural Stem Cell Self-Renewal in Young but Not Old Mice by Reducing p16Ink4a and p19Arf Expression
Jinsuke Nishino et al.
CELL (2008)
HMGA2, MicroRNAs, and Stem Cell Aging
Scott M. Hammond et al.
CELL (2008)
HMGA2 gene is a promising target for ovarian cancer silencing therapy
Anastasia Malek et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Mammalian cells cycle without the D-type cyclin-elependent kinases Cdk4 and Cdk6
M Malumbres et al.
CELL (2004)
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis
M Lazarov et al.
NATURE MEDICINE (2002)
分享论文
